|The following article features coverage from the 2021 ASCO Quality Care Symposium. Click here to read more of Cancer Therapy Advisor’s conference coverage.|
Several factors may help oncologists identify patients with metastatic breast cancer who are near the end of life, according to a study presented at the 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
Researchers set out to identify factors associated with 30-day mortality and develop a model that could predict 30-day mortality in patients with metastatic breast cancer.
The team analyzed data on 586,801 encounters with 9270 patients from the CancerLinQ Discovery database. The patients were separated into a training cohort (70%) and a test cohort.
The researchers found the following factors to be the greatest predictors of an increased risk of 30-day mortality (P <.05 for all):
- Chemotherapy within the past year but not the past 30 days (odds ratio [OR], 1.92; 95% CI, 1.67-2.20)
- Opiate use (OR, 1.71; 95% CI, 1.17-2.52)
- High pain score without opiate use (OR, 1.27; 95% CI, 1.10-1.48).
The greatest predictors of lower odds of 30-day mortality were (P <.05 for all):
- Body mass index change from baseline (OR, 0.28; 95% CI, 0.10-0.78)
- Serum albumin levels (OR, 0.38; 95% CI, 0.31-0.45)
- Performance status of 0 to 1 (OR, 0.73; 95% CI, 0.57-0.95).
The researchers developed a few candidate models for predicting 30-day mortality. The models’ prediction accuracy ranged from 70% to 89%, and the positive predictive values ranged from 31% to 77%.
The researchers’ next steps are to select a preferred model for clinical use and test it in the clinic.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Read more of Cancer Therapy Advisor’s coverage of ASCO QCS 2021 by visiting the conference page.
Ray EM, Zhang X, Dunham L, et al. Development of a breast cancer-specific prognostic tool using CancerLinQ Discovery. J Clin Oncol. 2021;39:(suppl 28; abstr 275). doi:10.1200/JCO.2020.39.28_suppl.275